-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JZoQslP+MEaCjHFsN2jq8cU/Rv5iroM6rHo8rVVd/eqlfyoooVCxGwbUCCCa7D2k
 0vVkOwBOScxmWYDKk/9lrg==

<SEC-DOCUMENT>0000921895-09-001238.txt : 20090430
<SEC-HEADER>0000921895-09-001238.hdr.sgml : 20090430
<ACCEPTANCE-DATETIME>20090430172413
ACCESSION NUMBER:		0000921895-09-001238
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090430
DATE AS OF CHANGE:		20090430
EFFECTIVENESS DATE:		20090430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUIGLEY CORP
		CENTRAL INDEX KEY:			0000868278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				232577138
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21617
		FILM NUMBER:		09785173

	BUSINESS ADDRESS:	
		STREET 1:		KELLS BUILDING
		STREET 2:		621 SHADY RETREAT RD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18901
		BUSINESS PHONE:		2153450919

	MAIL ADDRESS:	
		STREET 1:		PO BOX 1349
		STREET 2:		LANDMARK BLDG, 10 S CLINTON ST
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18901
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>defa14a03814_04302009.htm
<TEXT>
<html>
  <head>
    <title>defa14a03814_04302009.htm</title>
<!-- Licensed to: Olshan-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">UNITED STATES</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE
COMMISSION</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C.
20549</font></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SCHEDULE 14A</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Rule
14a-101)</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INFORMATION
REQUIRED IN PROXY STATEMENT</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SCHEDULE
14A INFORMATION</font></div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of
1934</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Amendment
No.&#160;&#160;)</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed by
the Registrant&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">x</font></font></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed by
a Party other than the Registrant&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></font></font></font></font></font></font></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box:</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Preliminary
Proxy Statement</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Confidential,
for Use of the Commission Only (as permitted by Rule14a-6(e)(2))</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Definitive
Proxy Statement</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">x</font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Definitive
Additional Materials</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting
Material Under Rule 14a-12</font></div>
      <div><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="80%" style="BORDER-BOTTOM: black 1px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">THE
      QUIGLEY CORPORATION</font></div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="80%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name
      of Registrant as Specified in Its Charter)</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="80%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="80%" style="BORDER-BOTTOM: black 1px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="80%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name
      of Persons(s) Filing Proxy Statement, if Other Than the
      Registrant)</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Payment
of Filing Fee (Check the appropriate box):</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">x</font></font></font></font></font></font></font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
fee required.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.</font></div>
      <div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left">
            </div>
          </div>
        </div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title
of each class of securities to which transaction applies:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Aggregate
number of securities to which transaction applies:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 36pt">
                <div>&#160;</div>
              </td>
              <td style="WIDTH: 36pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)</font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Per
      unit price or other underlying value of transaction computed pursuant to
      Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
      calculated and state how it was
determined):</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proposed
maximum aggregate value of transaction:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total
fee paid:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fee
paid previously with preliminary materials:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously.&#160;&#160;Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.</font></div>
      <div>&#160;</div>
      <div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amount
previously paid:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form,
Schedule or Registration Statement No.:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Filing
Party:</font></div>
      <div>
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date
Filed:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div>&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%; TEXT-ALIGN: center" align="left">
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April
30, 2009, Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley
Corporation, issued the following press release.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><img src="quigley_logo.jpg" alt=""></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR
IMMEDIATE RELEASE</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div>
              <table cellpadding="0" cellspacing="0" width="100%">
                  <tr>
                    <td align="left" valign="bottom" width="14%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CONTACT:</font></div>
                    </td>
                    <td align="left" valign="bottom" width="38%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Media</font></div>
                    </td>
                    <td align="left" valign="bottom" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Investor
      Relations</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="left" valign="bottom" width="38%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Karen
      Pineman</font></div>
                    </td>
                    <td align="left" valign="bottom" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carl
      Hymans</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="left" valign="bottom" width="38%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">G.S.
      Schwartz &amp; Co.</font></div>
                    </td>
                    <td align="left" valign="bottom" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">G.S.
      Schwartz &amp; Co.</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="left" valign="bottom" width="38%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">212.725.4500</font></div>
                    </td>
                    <td align="left" valign="bottom" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">212.725.4500</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="left" valign="bottom" width="38%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">kpineman@schwartz.com</font></div>
                    </td>
                    <td align="left" valign="bottom" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">carlh@schwartz.com</font></div>
                    </td>
                  </tr>
              </table>
            </div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Unexpected
positive finding expands potential for <br>Quigley QR333 drug for Diabetic
Neuropathy</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Findings
suggest possible disease modification</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Doylestown, PA (April 30,
2009)</font> Quigley Pharma Inc., <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.quigleyco.com</font>,&#160;&#160;a
wholly-owned subsidiary of The Quigley Corporation (NASDAQ: QGLY) announced
today that their recently completed Phase 2 double-blinded, placebo-controlled,
clinical trial of diabetic peripheral neuropathy, demonstrated a significant
improvement in two key measures of distal sensory nerve function in the group
treated with QR333.&#160;&#160;The compound was applied topically to the feet of
subjects suffering from painful diabetic neuropathy and over the course of 12
weeks, it significantly improved both maximal conduction velocity (p=0.05) and
compound sensory amplitude (p=0.05) in the sural nerve.&#160;&#160;These are
well established, validated and objective electrophysiologic measures of the
onset and progression of diabetic nerve damage.&#160;&#160;The mean improvement
in nerve conduction velocity was 1.5 m/sec, which exceeds the change considered
by thought leaders to be &#8220;clinically meaningful&#8221; in clinical
studies.&#160;&#160;The sural nerve carries sensation from the feet and its
pathology is the fundamental cause of foot pain and ultimately foot ulcers and
amputation in some diabetic subjects.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
positive findings were detected in compliant patients (approximately 50% of the
original intent to treat population) who had measurable nerve activity at both
the beginning and end of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">study.&#160;&#160;A
more conservative analysis involving approximately 65% of the randomized
subjects showed a strong, but non-significant, trend toward benefit for the
QR333 treated group. Other nerves evaluated for safety purposes were
unaffected.&#160;&#160;The electrophysiology testing was done as a safety
measure and was of interest because of the topical application of the study drug
to the area of the sural nerve.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
findings necessitate a change in the potential outlook for this investigational
new drug. The Diabetic Peripheral Neuropathy market has significant unmet need
for rational, mechanism-based drugs.&#160;&#160;These clinically significant
findings suggest disease modification in this (12 week) phase II (b)
study.&#160;&#160;The Company is aware that this is a finding in a subset of the
patient population.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%" align="left">
                </div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                </div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="right">
                </div>
              </div>
            </div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since the
observations obtained from the study relate to positive effect on nerve
functioning, we may, in the future, be focusing on a broader therapeutic
area.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">About The Quigley
Corporation</font></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Quigley Corporation (NASDAQ: QGLY, <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.Quigleyco.com</font>)
is a diversified natural health medical science company.&#160;&#160;&#160;Its
Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE&#174;
family of lozenges, gums and sugar free tablets clinically proven to cut the
common cold nearly in half.&#160;&#160;COLD-EEZE customers include leading
national wholesalers and distributors, as well as independent and chain food,
drug and mass merchandise stores and pharmacies.&#160;&#160;&#160;The Quigley
Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc.
consists of an FDA approved facility to manufacture COLD- EEZE&#174; lozenges as well
as fulfill other contract manufacturing opportunities. Quigley Pharma Inc.
(<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.QuigleyPharma.com</font>)
conducts research in order to develop and commercialize a pipeline of patented
botanical and naturally derived potential prescription drugs.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Forward-Looking
Statements</font></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Certain statements in this press
release are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and involve known and unknown risk,
uncertainties and other factors that may cause the Company's actual performance
or achievements to be materially different from the results, performance or
achievements expressed or implied by the forward-looking statement. Factors that
impact such forward-looking statements include, among others, changes in
worldwide general economic conditions, changes in interest rates, government
regulations, and worldwide competition.</font></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Important
Additional Information</font></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Quigley Corporation (&#8220;Quigley&#8221; or the &#8220;Company&#8221;) filed a definitive proxy
statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 2,
2009 in connection with the 2009 Annual Meeting of Stockholders and began the
process of mailing the definitive proxy statement and a WHITE proxy card to
stockholders. The Company&#8217;s stockholders are strongly advised to read Quigley&#8217;s
proxy statement as it contains important information. Stockholders may obtain an
additional copy of Quigley&#8217;s definitive proxy statement and any other documents
filed by the Company with the SEC for free at the SEC&#8217;s website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.sec.gov</font>.
Copies of the definitive proxy statement are available for free at
http://www.amstock.com/Proxy Services/ViewMaterial.asp?Co Number=07814. In
addition, copies of the Company&#8217;s proxy materials may be requested at no charge
by contacting MacKenzie Partners, Inc. at 1-800-322-2885 or via email at
quigley@mackenziepartners.com. Detailed information regarding the names,
affiliations and interests of individuals who are participants in the
solicitation of proxies of Quigley&#8217;s stockholders is available in Quigley&#8217;s
definitive proxy statement filed with SEC on April 2, 2009.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>quigley_logo.jpg
<TEXT>
begin 644 quigley_logo.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@%!@<&!0@'!@<)"`@)#!0-#`L+#!@1$@X4'1D>'AP9
M'!L@)"XG("(K(AL<*#8H*R\Q,S0S'R8X/#@R/"XR,S$!"`D)#`H,%PT-%S$A
M'"$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q
M,3$Q,3$Q,?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`^@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`1F"#+$`#N:-@V(;R\
MM[&U>YNYDAAC&6=C@`5,I**NR924%S-Z'(V/Q'L-1\0VVEZ?:22QSOL^T.VP
M#CLN,G]*XXXR,ZBA%?,X(X^$ZJIQ6_4[6NX]$*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`RM:\1:9HEQ;0:C<"%[DX
M3(X'N?05C4K0IM*3W,:E>%)I2>YP/QEUFZ5[33;>0I:31^:Y4\2<X`^@_K7G
MX^J](K8\O,JLE:"V,_\`MN?Q7X'FTHG;?::BS=>)XDX/XC.:S]JZ]%PZK\C+
MVSQ%!T^J_%&3X,T>XAU>QU2^DCTZRAD$OG7#A-X'90>3FL</3:DIRT2,,-2D
MIJ<M$NYZ_HOBC2M:OY[/3+CSW@4.S!2%(SC@GK7LTZ\*DFH/8]ZGB*=63C!W
ML;5;G0%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0!YC\8]"O[NXMM3M(7GABB\N14&2G).<>G/Z5Y6/I2DU)'C9C1G)J<5
M='*^![4Z[K,&BZF)9K,([!=Q!A.,Y4]N<<=.:Y,/'VDU3EL<6%C[6:I3V_(U
MKC2K;0O%<VCZ69[N&:)3/&B;I2,Y\K<.`#P2>.*V=.-.JZ<=?ZV-W2C2JNG#
M7OW]#&U/POK\NH%M2^SQ32G/[Z[B7'MC=P*QG0JN7O?FC">&JN7OVOZH]"^'
MOA^S\+P/->:A:27EWA/EE&T#LH]237HX:C&CJWJSU,'0CAU>4E=G<BN\](*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R_$LUU::1<W=G
M,L3V\;289-P;`Z5E5;C!M=#&LY1@Y1>Q:TT3_9$:YF$SN`V0FW&1TQ50O;4N
M%[:LQK77KIK*_=[.:1X)ID1XT&W"DXSD_G6*K/E;MM<YXUI<LG;:YJZ/<R7>
MC6=U-CS)H$D;'`R5!-;0DW!,WIR<H*3ZHRO"NH:EJ,%M<7?F[)4+'$*JGX'=
MG]*QHSG-)LPP]2<TF_Z_$Z.NDZSC_B,J:9IL6N682&^LYE*,!CS`QP4..H(_
ME7'BER1]I'='!C$J<%4CNBCX1T_7I-/>Z2&WT^YO299[NX4R3.3R-J\!0.P)
M_"LZ$*O+=:-]>IGAX57'F6C>[>YR.K?#KQ,+Z1MJ7Q=LF<2C+>YW<UQ3P=:_
M<X*F`K\W<Z'P/\-YK"_BU'6VC+0G='`AW?-V+'V]*Z</@G"7-,ZL+@'"2G4Z
M=#TNO4/8"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!DLL<,9>5U1%ZLQ
MP!2;2W$W8SO[=MI6*V,4]X1U,,>5'_`C@5E[5/X=2/:+IJ12ZU<P`M+H]YL'
M=0K?H#2=5K>+$ZC7V6.T[Q)IM_((HYC%*3C9*-IIPKPEH@C5C+0UZV-3'U_5
M+.TBEM]1M+A[:0;&8)E&!'3.:PJ5(QTDM#*I**5I+0CL/$5M=1@6-E>RHORY
M6(8'MG-*-92^%,4:B:]U&I#96\4$D4<02.8LSKZENOYULHJUC1025DBO/<1:
M7#%;Q6ES)$B!56"/<%4<`5+DH*UB=())(Q=%O]&2<)I5C?%H_EVJ&*IGV+8%
M84YTT[03T,:?LT_=3-V_U%;'!>VN91C),4>X+]:WE/DZ&\I<O0P+C6-%UJ\M
M2UO=W+VSF2.)8\C=ZD9YQ7.ZM.HUHW8PE*G4:NKV.DLKC[3$7\F6'!QME7::
MZHN_0Z4[BW=W;6<?F74R0KZLV*)24=V#DH[E!-?MYSBQ@NKL#C=%$=OYG`K-
M5D_A39G[1/X=0EU:[B&3H]T5]BI/Y`T.I)?98<[7V2I!XNM9KN*T6VN$GDD"
M%74#;]>:A8B+=K:DJLKVL;EQ-Y$#2%'?:/NHN6/T%=#=E<V;L8EQXNL+64Q7
M$-W'(/X6BP?YUSO$1CHTS%UHK1FGI^H_;6XM+J%<9#2H%!_6M83YNAI&5^A=
MK0LAN[C[-`TOE22[?X8EW,?PJ9/E5Q-V,6/Q?827'V=(+PS9(\L1?-D=L9K#
MZS&]K,R5:-[%S^V1CC3M0_[\?_7J_:^3*Y_)E6Z\56MHZI<6=[$S?=#18S].
M:EXA1W3)=9+1IFI>7GV2%9#;SR[OX8DW$?6M92Y5>QHY65[&3%XOT^:80PPW
M;RDX""+G^=8K$Q;LD9*M&]D;EO+YT*2&-X]PSM<88?6NA.ZN;)Z%35=5BTM0
M\\,[1XR7C3(7ZFHG45/<F4U#<K6'B*WOW1;6UO'5F"^9Y7RCZG-1&LI;)DQJ
MJ6R-BMS4J:MJ$.F6,EU.?E0<`=6/85$YJ$;LF4E!79RFC17/BN]>[U)B+*%L
M+"IPI/I_]>N.FI5Y7EL<T$ZKO+8[.&)(8Q'$BQHO`51@"NY)+1'4E;1#Z8SC
MO'^E0K;+J,*".56"R;>-V>A^M<.*II+F1RUX*W,C2\$:A+?Z/^_8M)`_E[CU
M(P"/YUKAIN4->AI1DY1U,[XCW>VWMK-3R[%V'L.!_,UGBY:*)GB'HD;_`(=L
MQ8Z-:P8PP0,W^\>3712CR02-Z<>6*1HUJ607TXM;*:=N!$A;\A4R?+%L3=E<
MQ/`EIY.CFY<?O+IRY/?&<#^OYUAAHVA?N8T%:-^YJ:]<_8]'NI\X*QG'U/`_
MG6M67+!LTF^6+9S?PWM`([J[8<DB-3^I_I7+A([R.?#QW9L^*-;71K,%`&N)
M.(U/3ZFMZU54UYFU6IR(Q/#>BR:PPU36G:=6/[N-CP??'I[5A1I.I[\S&G3Y
M_>D=E&BQH$C4*HX``P!7=L=>PZ@#-O=%@NM4M;_.R6W.3@??],UE*DI24NQF
MZ:<E(TAQ6IH>?R(-5\>E2-T<<F#]$'^(KS6O:5['$USU3T"O2.T*`&R.(XV=
MN`H)-)Z`]#A/!"&\\175ZP^Z&?/NQ_PS7GX?WJCD<5!7FV=[FO1.TS+ZWL]4
MNXHFES+92"4H/T!K*48S=NQG)*3MV-/M6IH<-XSTM]-OH]7L,H"P+[?X7]?Q
MKS\13Y)<\3CK0Y7S(Z&P\06D^CK?S2",#Y77N&]`._M73"M%PYC>-5./,R`6
M-SKLBS:DK060.8[7."_H7_PJ>1U7>6W8GE=1WEL;D4:0QK'$BHBC`51@"NA)
M+1&Z5MA],#COB4[BWL4&?+9G+?4`8_F:X<9>R.7$;(U?!*(GAVVV8^;<6^N3
M6V'_`(:-*.D$;E=!L%`'(?$2_46L-A&=TDC!V`[`=/S/\JXL5/111RXB6G*C
M5\'Z<^F:,B2C;+*?,<>F<8'Y"MJ%/DAJ:48<D=3F=>/]I>-HK8_<1TC_``ZG
M^9KDJ>_6L83]ZK8[\#`P*])':+0!@^,YR-,6RAYGO'$:J.N,\_Y]ZY\0_=Y5
MNS&L_=LNIL65NMI:0VZ?=B0*/P%;17*DC6*Y58Y[XAW7E:3'`IP9I!^0Y_GB
MN;%2M"QAB':-B_X/M?LOA^V4C#.#(?Q.?Y8K3#QY::+HJT$<G\0V<ZX@;(58
M5V_F<UQXKXSFQ'Q'>:<L:6%NL./+$:[<>F*]&'PJQV1V18JBC(UFWNXX;F[@
MU2:`(A<1[$*C`]QFL*D9)-J5C*::NTS!\*WVL:U<2B;47CBA`)VQIDDGIT^M
M<]"=2H]]#&E*<WN=?>3"VM)IV.!$A8_@*[9/E39U-V5SC/AY"9]1O+UQR!C/
MNQR?Y5PX57DY')AU>3D=S7H'8%`&3XLNOLF@W3@X+KY8_P"!<5C7ERTVS.J^
M6#,#P7HKS:<]T;NYM_-;`$+;<@=S^.:YL/2;CS7L84:=XWO8W)=!=U(&JZ@#
M_P!=?_K5T>Q?\S-O9^;&>$=.FT^RG%V")Y)F)9CDL.@-*A!P3N*E!Q6IN5T&
MQG>(VC30[QI@"GE'@^O;]<5E5LH.YG4^!W.6^'NFQ3R37DR!_*(6//0-U)^O
M2N3"P3O)G/AX7U9W6*]`[`H`*`*&N:7#JUBUO-\IZHX'*GUK.I352-F1."FK
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MTW?FGN$8._-+<OWEW'9QAY%D8$X`C0L?R%:2DH[FC?*</XO>\U>^C-M8W7D1
M)A=T1&23R?Y5Y]=RJ2T6AQU;S>B.QTB\CN(1%%#/"(E`Q+&5KNIR35DCJA)-
M616\2:#%K,"_-Y4\?W'Q^A]JBK151>9-2FIHR=*N-:T&,6M[8275LGW'A.XJ
M/\/K6,'4I:25T9Q<Z>C6AKQ>(K)@-Z7,3>CV[_T%;JO$T56)E^)]8>\TY[33
M;2ZD,O#.864`?B*QK57*/+%,SJSO&T46_`^GRV&DDW$9CEF<L588('0?Y]ZO
M#P<(:E48N,=2OXIU1[K3I;/3[6ZD>0[6;R6``SSU%37J-QY8H56;<>6**_@^
M?^R;"2&ZLKQ97D+$B$D8P,5%!^SC9IDTGR*S1L3>(88U)2SOG/8"`C^=;NLE
MT9JZJ71D&B/?:E?R:A>)+:PQCRX8"2,^K$=ZFFY3ESO04.:3YGH9/C.\EU**
M*UL;:Y=$<L[>4P!(X';ZUCB).:Y8HRK-R5HHT=!U1++2K>VDL+U'C3#8A)!/
M<UK2J*,4K,TA/EBE9EV7Q!$BDK8WSGT$!%:.LET93J)=&5M'N-0U74S=W$4M
MG:0`K'$Q(+L>Y]:BFYSES/1(4'*<KO1&\[!$+'.%&>!71LC8Y/Q9J,NHZ=]D
ML+*[;>P+L82!@<_SKCKS<X\L4SFJR<E9(?X.N5T^P2SGM;J.9Y"2?).#GIS3
MP\N2/*TPHOE5FCJZ[#I"@`H`*`"@#G?%GAP:J@GM=J72#'/`<>AKFKT.?5;F
M%6ESZK<Q]#UVZT%18ZO:S+"A^5MO*_XBL*=65+W9HRA4=/W9(Z:W\1:1.H*W
M\*>SMM/ZUU*M3?4Z%5@^I<M+VUO-WV6>.;;UV-G%:1G&6S*4D]BKJ&KQVMVM
MG##-=7;+O\F$#*KZL20%'U-3*HHOE2NR)U5%\J5V26-Y<33-%<Z?/:D+N#,R
MLI]L@]:<9-NS5AQE)NSC8?J>HV^F6XFN"WS,$1$7<SL>BJ.YHE-05V.<U35V
M4I-9N88S-<:/>QP`9+*4=E'J5#9_+-1[22U<78S=62U<78TK6XAN[:.XMI%D
MBD4,K+T(-:1DI*Z-8R4E=&/=^)XK66^WV5RT%@X6>9-I"Y`.<9R1@^E8NLHW
MTT1A+$*+EH[+<W%8,@9>A&170=)A'Q3"OGR265REK!<FV>X^0J&#;<XSG&?:
MN?VZUTTO8Y?K"U=G:]C<D=(XVD=@J*,DG@`>M;WMJ=+=M3)AUN6[C\[3],NK
MBW/*RY2,./50Q!(]^*R55RUC'0P59R5X1;1;TO4X-1$HB#Q2PMMEAE7:\9[9
M'OZ]#50FI;&E.HI[="+5=6%A>6MJEK-<S76\HL94?=`)SN(]:4ZG(TK;DU*O
M))12NV3:/J4.J6K3P*Z;)&C=)!AE93@@XX_*JA-35T53J*HKH?JE_!IEC+=W
M!.R(9P.K'L![D\43FH1YF.I-4XN3$TJ_@U*PBN[;.R09P1@J>A!'8@\40FIQ
M4D%.:J14D5-;UA](42/8SS0EE3?&R8W,<`8)!ZD5%2HZ>MC.K5]EKRZ%^TED
MF@#RV[V[G/R.02/R)%:1;:U5C6+;6JL0V6HQ7=[>VJ(RO9NJ.3T)*YX_.IC-
M2DUV)C44I./8;J>J0:>T4;+)-/,2(H(ER[XZ\=@/4\42FH674)U%!I=7T*LV
MN/9)YFI:=<VEOWFRKJGNVTD@>_2H=5QUDK(S=9PUG&R-@$,H(.01P16YT&3H
M_B&QU2::"%FBGAD=#'(,%MK%25]1D=JQIUHS=D84Z\*C:6Y:MM1BGU2ZL%1Q
M):JC,QZ'=G&/RJU-.3CV+C43FX=B[5F@4`%`!0`4`%`#717&&4$>A%%@(A96
MH.1;0@^OEBIY8]B>5=B5$5.$4*/88JK6*2L8]UI]Y;:U+JFFB*4SQK'/!*VW
M=MSM*M@X/)XQS6$H24^>)SRA*,^>'7<N6,^HS2G[7916L07C$V]B?P&`*N+F
MWJK&D7-OWE8AUW3);];:6UD6*ZLY1+$7&5)P001Z$$TJD'*S6Z)JTW.SCNB*
M2?798S%'86UO(1CSFN-ZK[A0H)^G%2W5>EK?,ERJM644OG_P"WHNFII.E6]C
M$Y=85QN/5CG)/YDUI3A[.*BNAI3IJG!170YZ\\*W,VI7^H+Y3RM<++%#(Q,4
MJA%!5UZ`Y'![5RRP[<G)=SDEAFYRGY_(ZR/<8EWH$;`RH.<'TKL.Y;&#HWAJ
M&"6ZFU"!)99+V6XCRQ90"V5..F?PKGIT$FW)=3FIX=)MR6MVS:O[5+VRGM9<
MB.:-HVQUP1@UO**DFF=$HJ47%F59#6M.M(K,V=O>K"H1)EF\K<`,#<I!P?IF
ML8^T@E&US"/M::4;7MUN3:+ID]O>7FH7SH;J\V`I%G9&J@X4$]>IR:JG!Q;E
M+=E4Z;C)SENRKXFT"36K^Q)D:*"%90[QR%74L!M(Q[BHJT74DOF17H>UE'LK
ME[P]:SV.G+:W,,$;1$@-`,+(/[V.Q/<>M:4HN,;,UHQ<(\K7W%75M(NM6U6$
MS3M;V5J!)'Y1!9Y?4@@C`'3W/M4U*;G)7=DC.I2E4FKNR7YAI.D76D:K.89V
MN+&Z'F2>:0&27U```P1U]Q[T4Z;IR=GHPITI4YNST?YECQ-I\VI::MO;;0XG
MBD^8X&%<$_H*JM!SC9>1=>#G&R[HTQP*U-C,TK3YK35M5N9=OEW<B-'@\X"`
M'/XUE"#C*3?4QIP<9RD^HS5M-N7U*VU/3VC^TVZ-&8Y<A9$8@D9'0Y`YI3@^
M93CNA5*<N93CNB#48M8U>SEL6M8+"*92DDIF\TA3UVJ`.?<_E4S52HG&UB)J
MI4BXVM^)M6\*V]O'#$"$C4*N3V`Q6Z5E9'2ERJR,/3?#B?V9+;:B@\PW4T\4
MD38>/<Y8%6Z@X-<\*/NVEW?YG-"@N5J?=CM`TF_L-8U"YOKA;E9XXECE`VL0
MN[[P]>>HZTZ=.4)MR=[V'2I3A.3D[WL;U=!TA0`4`%`!0`4`%`!0`4`%`!0`
L4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
